Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.

Chapman, Thomas P.; Frias Gomes, Catarina; Louis, Edouard; Colombel, Jean-Frédéric; Satsangi, Jack

doi:10.1111/apt.16113

Download

Article (Scientific journals)

Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.

Chapman, Thomas P.; Frias Gomes, Catarina; Louis, Edouard et al.

2020 • In Alimentary Pharmacology and Therapeutics, 52 (10), p. 1621

Peer reviewed

Permalink
https://hdl.handle.net/2268/254795

DOI
10.1111/apt.16113

PubMed
33085981

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Letter_rationalising aminosalicylates in IBD-authors reply_Aliment Pharmacol Ther_PPE.pdf

Publisher postprint (180.05 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

aminosalicylates; IBD; authors' reply

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Chapman, Thomas P.

Frias Gomes, Catarina

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Colombel, Jean-Frédéric

Satsangi, Jack

Language :

English

Title :

Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.

Publication date :

2020

Journal title :

Alimentary Pharmacology and Therapeutics

ISSN :

0269-2813

eISSN :

1365-2036

Volume :

Issue :

Pages :

1621

Peer reviewed :

Peer reviewed

Additional URL :

https://onlinelibrary.wiley.com/

Commentary :

This article is linked to Chapman et al and Nicolaides et al papers. To view thses articles, visit https://doi.org/10.1111/apt.15771 and https://doi.org/10.1111/apt.16107

Available on ORBi :

since 06 January 2021

Statistics

Number of views

83 (4 by ULiège)

Number of downloads

61 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Nicolaides S, Vasudevan A, van Langenberg D. Letter: rationalising aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1618-1618.
Chapman TP, Frias Gomes C, Louis E, et al. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:73-84.
Singh S, Kim J, Zhu W, et al. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020;52:481-491.
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an International Registry. Gastroenterology. 2020;159:481-491.e3.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
Grundy EJ, Suddek T, Filippidis FT, et al. Smoking, SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice. Tob Induc Dis. 2020;18:58.